Blood thinner after heart procedure: hope for artery health, but trial stopped short

NCT ID NCT03630055

Terminated Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether taking the blood thinner rivaroxaban for 7 days after heart catheterization via the wrist could prevent the wrist artery from becoming blocked. About 930 adults were planned, but the trial was stopped early. The main goal was to see if the artery stayed open at 30 days, while also checking for major bleeding risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rivaroxaban (Xarelto), a blood thinner
What this could lead to: If it worked, a short course of rivaroxaban could reduce the risk of radial artery blockage after heart catheterization, preserving the artery for future use.
What could go wrong: The trial was terminated early, so we don't have enough data to know if it works or is safe. Blood thinners like rivaroxaban also raise the risk of bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RADIAL ARTERY OCCLUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arterial occlusion Arterial Occlusive Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RADIAL ARTERY OCCLUSION

Contacts and locations

Locations

Kingston Health Sciences Center

Kingston, Ontario, K7L 2V7, Canada
Mayo Clinic

Rochester, Minnesota, 55905, United States
University of Ottawa Heart Institute

Ottawa, Ontario, K1Y4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.